M&A Deal Summary

Viatris Acquires Abbott - Non-U.S. Developed Markets Specialty and Branded Generics

On February 27, 2015, Viatris acquired medical products company Abbott - Non-U.S. Developed Markets Specialty and Branded Generics from Abbott Laboratories for 5.3B USD

Acquisition Highlights
  • This is Viatris’ 3rd transaction in the Medical Products sector.
  • This is Viatris’ 3rd largest (disclosed) transaction.
  • This is Viatris’ 4th transaction in the United States.

M&A Deal Summary

Date 2015-02-27
Target Abbott - Non-U.S. Developed Markets Specialty and Branded Generics
Sector Medical Products
Buyer(s) Viatris
Sellers(s) Abbott Laboratories
Deal Type Divestiture
Deal Value 5.3B USD

Target

Abbott - Non-U.S. Developed Markets Specialty and Branded Generics

United States
Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Viatris

Canonsburg, Pennsylvania, United States

Category Company
Founded 1961
Sector Life Science
Employees33,000
Revenue 15.4B USD (2023)
DESCRIPTION

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.


DEAL STATS #
Overall 8 of 13
Sector (Medical Products) 3 of 3
Type (Divestiture) 3 of 6
Country (United States) 4 of 6
Year (2015) 2 of 2
Size (of disclosed) 3 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-02 Famy Care

Mumbai, India

Famy Care Ltd is a family owned pharmaceutical manufacturer based in India. The company specializes in the women’s healthcare market, specifically contraceptive formulations and devices.

Buy $750M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-10 Meda

Solna, Sweden

Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.

Buy $9.9B

Seller(S) 1

SELLER

Abbott Laboratories

North Chicago, Illinois, United States

Category Company
Founded 1888
Sector Medical Products
Employees114,000
Revenue 40.1B USD (2023)
DESCRIPTION
Entrance to Abbott's corporate campus in Abbott Park, Illinois.
Entrance to Abbott's corporate campus in Abbott Park, Illinois.

Abbott Laboratories is a diversified, global provider of diagnostics, medical devices, nutrition and pharmaceuticals. Abbott Laboratories was incorporated in 1888 and is headquartered in North Chicago, Illinois.


DEAL STATS #
Overall 5 of 8
Sector (Medical Products) 3 of 5
Type (Divestiture) 3 of 6
Country (United States) 4 of 6
Year (2015) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-29 Topera

San Diego, California, United States

Topera, Inc. has developed a novel diagnostic catheter and mapping software, or rotor identification system, which help physicians identify and target the specific areas of a person’s heart that are perpetuating atrial fibrillation.

Buy $250M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-30 Tendyne Holdings

Roseville, Minnesota, United States

Tendyne Holdings, Inc. is a medical device company focused on developing minimally invasive mitral valve replacement therapies.

Buy $250M